Stocksigma LogoStocksigma Logo

Evonile Pharma Receives BSE In-Principle Approval for ₹9,000 Million Rights Issue

Evonile Pharma Limited (formerly Novartis India Limited) secured in-principle approval from BSE on 30th Oct'26 for its proposed rights issue of partly

Evonile Pharma Receives BSE In-Principle Approval for ₹9,000 Million Rights Issue

Novartis India Ltd · Others (Uncategorized) · 01 Nov 2026, 7:54 pm

Evonile Pharma Receives BSE In-Principle Approval for ₹9,000 Million Rights Issue Evonile Pharma Limited (formerly Novartis India Limited) secured in-principle approval from BSE on 30th Oct'26 for its proposed rights issue of partly paid-up equity shares aggregating up to ₹9,000.00 million. The company's Board of Directors and Rights Issue Committee will meet on 4th Nov'26 to approve the Letter of Offer and determine key issue terms, including the issue price, entitlement ratio, and record date.

Original exchange filing (PDF)

More announcements from Novartis India Ltd

All Novartis India Ltd announcements